Nektar Therapeutics' stock plummeted 5.13% during intraday trading on Monday, following a negative analyst action.
The sharp decline came after investment firm Wedbush cut its price target on the biopharmaceutical company to $80 from $95, while maintaining its Neutral rating. Analyst price target reductions often signal concerns about a company's future earnings potential or valuation, which can trigger selling pressure from investors.